• Regulatory NewsRegulatory News

    Asia Regulatory Roundup: India Allows Parallel Submission of Trial Filings for Insulins, mAbs (9 August 2016)

    Welcome to our Asia Regulatory Roundup, our weekly overview of the top regulatory news in Asia. DCGI Allows Parallel Submission of Clinical Trial Filings for Insulins, mAbs The Drug Controller General of India (DCGI) has cleared clinical trial sponsors to submit applications to his office and the Review Committee on Genetic Manipulation (RCGM) simultaneously. By moving from sequential to parallel filings, DCGI has potentially shortened the time it takes for de...